Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Buys 33,726 Shares of Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker purchased 33,726 shares of Kodiak Sciences stock in a transaction dated Tuesday, September 29th. The stock was bought at an average price of $85.05 per share, with a total value of $2,868,396.30. Following the completion of the purchase, the director directly owned 20,191,214 shares of the company’s stock, valued at approximately $1,717,262,750.70. This trade represents a 0.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, September 28th, Bros. Advisors Lp Baker acquired 807,840 shares of Kodiak Sciences stock. The shares were bought at an average price of $72.57 per share, for a total transaction of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 418,323 shares of Kodiak Sciences stock. The stock was bought at an average price of $83.58 per share, for a total transaction of $34,963,436.34.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 681,866 shares of Kodiak Sciences stock. The stock was bought at an average cost of $88.77 per share, with a total value of $60,529,244.82.

Kodiak Sciences Stock Up 4.0%

KOD traded up $3.68 during mid-day trading on Wednesday, reaching $94.80. 4,897,441 shares of the company traded hands, compared to its average volume of 1,094,203. The company’s fifty day moving average price is $40.26 and its 200-day moving average price is $38.27. The stock has a market capitalization of $5.96 billion, a P/E ratio of -22.63 and a beta of 2.18. Kodiak Sciences Inc. has a 52-week low of $10.94 and a 52-week high of $98.80.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). As a group, sell-side analysts forecast that Kodiak Sciences Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KOD. Engineers Gate Manager LP boosted its position in shares of Kodiak Sciences by 145.8% in the second quarter. Engineers Gate Manager LP now owns 29,537 shares of the company’s stock worth $1,151,000 after purchasing an additional 17,520 shares during the period. Squarepoint Ops LLC boosted its holdings in Kodiak Sciences by 112.6% in the 2nd quarter. Squarepoint Ops LLC now owns 151,098 shares of the company’s stock worth $5,887,000 after buying an additional 80,042 shares during the period. Arizona State Retirement System increased its stake in Kodiak Sciences by 6.9% in the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after buying an additional 554 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Kodiak Sciences in the 2nd quarter worth $232,000. Finally, Wellington Management Group LLP raised its holdings in Kodiak Sciences by 81.9% during the second quarter. Wellington Management Group LLP now owns 793,613 shares of the company’s stock valued at $30,919,000 after acquiring an additional 357,284 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on KOD shares. Wall Street Zen lowered shares of Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research report on Saturday. JPMorgan Chase & Co. boosted their target price on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. HC Wainwright upped their target price on shares of Kodiak Sciences from $58.00 to $96.00 and gave the company a “buy” rating in a report on Monday. Jefferies Financial Group reiterated a “buy” rating and issued a $112.00 price target on shares of Kodiak Sciences in a research report on Monday. Finally, UBS Group lifted their price target on shares of Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $100.43.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Kodiak said Zenkuda and tabirafusp-ted achieved the primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration, reportedly matching Eylea on efficacy while supporting the potential benefits of longer-lasting eye treatments. The results are the main catalyst behind the stock’s sharp increase. KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
• Positive Sentiment: The company is advancing Zenkuda toward a Biologics License Application filing, strengthening expectations that Kodiak could move from a development-stage biotech toward a commercial product opportunity. Kodiak Sciences Inc. Advances Zenkuda Toward Filing
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $96 price target while raising its long-term EPS forecasts, including estimates of $1.76 for fiscal 2029 and $5.81 for fiscal 2030. It also improved its fiscal 2028 loss estimate, though its fiscal 2027 loss forecast worsened slightly. HC Wainwright Kodiak Sciences analyst estimates
• Positive Sentiment: Additional analyst coverage from Lifesci Capital, UBS Group and HC Wainwright has pointed to higher valuation potential following the clinical update. Kodiak Sciences Stock Gets Price Target Boost from Lifesci Capital
• Neutral Sentiment: Unusually high put-option buying indicates that some traders are hedging or positioning for a pullback after the sharp rally, but it does not by itself establish a fundamental change in the company’s outlook. Kodiak Sciences Stock Sees Unusually High Put Option Buying
• Negative Sentiment: Despite the clinical success, Kodiak remains a cash-burning biotech with no revenue and ongoing development expenses. Analysts and commentators warn that a potential share offering could fund operations but dilute existing shareholders, making the stock’s sharp repricing difficult to chase. A $32 Biotech Became a $90 Biotech Overnight

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.